Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
![Appraising ultra orphan drugs cover page](https://www.ohe.org/wp-content/uploads/2018/03/Appraising-ultra-orphan-drugs-cover-page_0.jpg)
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.